The antisense drug everyone has dosed the longest turns out to bend its gene, and a shared well turns a hundred million cells into a thousand observations

Nusinersen, the splice-switching oligonucleotide given to infants with spinal muscular atrophy since 2016, also activates its target gene's promoter thirty kilobases away, by a mechanism the splicing assay the field runs cannot see. In the drug-screen atlas on which much perturbation modelling is pretrained, cell lines that shared a well move together, and the effect shows up in wells where no drug was given. A benchmark of de novo peptide sequencing finds the errors are the same whichever model makes them: what is missing is fragment ions, not decoder capacity. Switzerland has stopped generally requiring comparative efficacy trials for well-characterised biosimilars, following the European regulator. The aldosterone-to-renin ratio, a two-value test for a common and treatable cause of high blood pressure, is today's medicine concept.

Connecting the dots

What counted as one observation. A preprint on the Tahoe-100M drug screen reports that "In each test the cell lines of a well share a component of expression that a replicate well does not reproduce" (arXiv), which connects with the finding, from pooled CRISPR screens, that splitting the cells of one transduction counts the same clones twice. In both the reported quantity was a property of the chosen unit. Today's benchmark of protein prediction from stained slides makes that choice explicit and uneven, holding out patients in some cohorts and regions in others (arXiv), and a survey of two thousand clinical prediction papers finds the published numbers disagree with their own arithmetic: "around 1 in 8 ROC curves did not match their reported AUC value" (medRxiv).

A second mechanism, outside the assay. The antisense item below sits beside the recent finding that measuring knockdown with a probe overlapping the drug inflates the answer. There the readout chosen decided the size of the effect; here it decides whether a whole mechanism is visible at all, for the oligonucleotide with the longest clinical record.

Evidence moving off the clinic and onto the bench, except where it does not. Swissmedic now says comparative efficacy studies are "no longer generally required" for well-characterised biologicals (Swissmedic, translated from German), so analytical comparability plus pharmacokinetics can stand in for a trial. On the same regulatory calendar, a US advisory committee looked at a myopia eye drop whose trial met its threshold and was unconvinced, because "small shifts or sensitivity analyses around missing data easily erased the statistical effect" (Review of Myopia Management).

Redesign with nobody's budget increased. Trieste kept the asylum's money and its director and turned both into a community service; Emilia-Romagna paid to train one reference gynaecologist per public birth unit and the share of women delivering vaginally after a caesarean rose; today's book argues that most trouble sits in the system rather than in the person working in it. Three accounts of changing an organisation with no new equipment in any of them.

New concepts

An antisense drug bends the gene it is dosed against, and the splice correction is not what does it

Nusinersen's target site sits near the far end of SMN2, the gene whose splicing it corrects. The claim is that the oligonucleotide also reshapes the gene in three dimensions and switches on the promoter tens of kilobases away — and that the two effects are separable. Knocking down the protein that loads cohesin, the ring complex that holds chromosomal loops together, removes one and leaves the other intact.

"This clearly indicates that promotion of looping and regulation of alternative splicing are two independent mechanisms caused by ASO1." — bioRxiv preprint

The authors mark the boundary themselves: "ASO-mediated gene looping was found and characterized in cultured cells. Its existence in a whole organism exceeds the scope of the present report."

Why it matters: the assay that would detect this is cheap and standard — a chromosome conformation measurement anchored on the promoter — but it is not the splice-ratio readout the field runs, so anyone interrogating oligonucleotide libraries for mechanism is choosing, through the assay, which mechanisms can appear.

In a pooled screen the well is the observation, and the evidence is in the wells where no drug acted

Tahoe-100M pools many cell lines into each well of a drug screen. The cleanest demonstration of the artefact is in the solvent-only controls, where any shared shift cannot be a drug effect.

"In each test the cell lines of a well share a component of expression that a replicate well does not reproduce." — Huang, arXiv, CC BY 4.0

"Between the two untreated control wells of a plate, where no drug acts, the same test calls 5 of 13 plates significant" — same

Re-scoring three released models with the input taken from a replicate well instead of the same well costs each of them roughly a quarter to a third of its score. The obstacle to fixing it is prosaic: the plate layout is not published, and the author reconstructs well positions from sample numbering.

Why it matters: the headline splits in this literature hold out whole cell lines and whole perturbations, so what leaks is the residual well structure inside a properly held-out line — and the remedy, treating the well as the unit, shrinks a hundred million rows to something on the order of a thousand.

Figure 1, Huang, arXiv 2026, CC BY 4.0, link — in an untreated well the cell lines shift together, while two halves of the same well do not.

The ceiling in peptide sequencing is the spectrum, not the model

Eight de novo models, three datasets, scored against database-search identifications. Reading a peptide's sequence from a fragmentation spectrum requires that the fragments distinguish the candidates; often they do not.

"Most sequencing errors were model-independent and driven by limited fragment ion coverage, a limitation also observed in database searches with large search spaces." — van Puyenbroeck et al., Nature Methods

"Realizing this will require de novo sequencing to move beyond improving sequence prediction alone, toward strategies that quantify the inherent ambiguity of a fragmentation spectrum." — same

Where every cleavage site had its complementary ion pair, an idealised ensemble was right nine times in ten; missing three pairs took it to one in two. What resolved candidates best was not a better spectrum score but an independent physical property, retention time predicted from the sequence.

Why it matters: for the half of acquired spectra that identification leaves on the floor, this says how much of that is irreducible, and it puts recalibrating a confidence score downstream of a distinction the fragmentation never made.

Atlases and datasets

Protein prediction from a stained slide, scored per cell across seven cohorts

Haematoxylin and eosin is the cheap routine stain; multiplexed immunofluorescence is the expensive molecular measurement. Seven cohorts where both were acquired on the same section — colorectal and breast cancer, a multi-tumour array, head-and-neck metastases, bone marrow, glioma — give a benchmark that asks for each protein in each cell visible to the model.

"We introduce CellPlex, a benchmark that poses the task at the level of the cell" — Gao et al., arXiv, CC BY 4.0

Two results outrank the leaderboard. Predictability belongs to the tissue rather than to the protein — "CD3 reaches 0.66 PCC on Orion-CRC but 0.20 on glioma, and Ki67 0.74 on bone marrow but 0.30 on the Multi-tumor array." — and "Transfer works only between closely related cohorts:". What governs accuracy is whether the protein follows tissue architecture, not how abundantly it was measured.

Why it matters: substituting a cheap acquired image for an expensive assay works for some proteins in some tissues, and the accuracy measured on one tissue is not a number you can carry to the next.

Figure 3, Gao et al., arXiv 2026, CC BY 4.0, link — what makes a protein predictable from a stained slide, across cohort–protein pairs.

Methods

Protein interactions mapped inside a piece of human tissue, down to a needle biopsy

Which proteins touch which has mostly been established in live cells, lysates and engineered organisms — not in the diseased human tissue where a drug target has to act.

"Here we describe MAP-IT, an optimized photocatalytic carbene-based proximity labeling method" "for direct PPI mapping in primary human tissue sections" — Faulkner et al., Nature Communications

An antibody delivers a photocatalyst to the chosen protein; visible light generates a short-lived reactive species that tags only immediate neighbours, read afterwards by mass spectrometry. The illumination is patterned by micromirrors under the guidance of an image-segmentation network, so the question can be asked of a chosen region of the section. The authors report new interactors of the EGFR receptor in colon cancer, validated by independent assays.

Why it matters: the measurement is the interaction itself rather than an abundance, in solid primary tissue, with an input small enough to come from a diagnostic biopsy.

Clinical trials

A pivotal trial in Becker muscular dystrophy missed, and the sponsor says it disagrees with its own earlier data

"no statistically significant benefit on the North Star Ambulatory Assessment (NSAA)." "Secondary endpoints also were not met." — Servier

Eighteen months, placebo-controlled, on a functional motor scale. No effect size has been released, and the company says the result is not aligned with findings from the earlier phase 2 study.

Better pictures before breast surgery, and the same operations

Contrast-enhanced mammography before surgery was randomised against standard imaging in early breast cancer, with a pre-set target that it should change treatment in one patient in ten.

"This trial did not meet its primary end point of a 10% treatment change" "preoperative CEM improved malignant extent estimation" — PubMed

Mastectomy and reoperation rates were indistinguishable between the arms.

Why it matters: the trial cleanly separates seeing the tumour's extent better from doing anything different about it.

An on-screen prompt raised testing for a treatable cause of hypertension; the diagnoses did not follow

Clinicians, not patients, were randomised, covering more than twelve thousand people with high blood pressure and a risk feature. Test orders rose from 98 of 6,392 patients to 401 of 6,109. New related diagnoses were 13 against 12 (ClinicalTrials.gov); the record posts no between-group estimate.

Why it matters: a software nudge inside the clinical encounter was tested at scale on the behaviour it targets, and the record also posts what happened downstream within six months.

Elsewhere: protons did not improve survival over photons in liver cancer, reported early after an interim futility analysis, with about half the rate of severe treatment-related adverse events (ClinicalTrials.gov).

Hospitals

Italy: money for allowances, not for hiring

"Non c'è un euro per un vero piano straordinario di assunzioni, nonostante la gravissima carenza di medici e infermieri." (translated from Italian: "There is not one euro for a real extraordinary hiring plan, despite the very serious shortage of doctors and nurses.") — Quotidiano Sanità

The sentence is from a hospital doctors' union now seeking joint action with others. Separately, patients will receive a statement of what their outpatient care cost the national service — "Non si tratta di una fattura da pagare, né di un nuovo ticket." ("This is not a bill to pay, nor a new co-payment."), with no extra funding for issuing it.

Spain: primary care gets faster, hospital specialists get slower

"El tiempo medio para lograr consulta con un especialista hospitalario tras ser derivado empeora hasta los 139,58 días" (translated from Spanish: "The average time to get a hospital-specialist appointment after referral worsens to 139.58 days") — Redacción Médica

The same public barometer has primary-care waits falling to under ten days. Mental health is the other exception, and two in five patients say they would rather go private.

Why doctors leave is not the mirror image of why they stay

"the reasons people leave are not simply the inverse of the reasons they stay." — Hysong and Soong, BMJ Quality & Safety

The editorial puts replacing one US physician at a quarter of a million dollars to over a million, and describes several distinct exit paths rather than burnout alone. Alongside it, an analysis in England finds that "Three in 20 ambulances reaching patients with a life-threatening emergency have no paramedic as part of their crew" (HSJ).

The electronic record bill that arrives after go-live

"Each linked account, and each request a patient enters into ChatGPT, generates API calls against Advocate's Epic EHR." — Becker's Hospital Review

The quote is from an executive at a large US system. One cancer centre attributed $177 million of its operating expense growth last year to go-live support and training, and pricing increasingly mixes flat fees with charges tied to model use.

Why it matters: patients routing their own questions through a chatbot now generates metered traffic against the hospital's record system, a cost line nobody budgeted when the system was bought.

Medicine concept of the day

The aldosterone-to-renin ratio: a guideline now suggests it for everyone with hypertension, and almost nobody is tested

High blood pressure is usually treated without asking why it is high. This pair of blood values asks one specific question.

"Primary aldosteronism is a disorder caused by autonomous production of aldosterone by the adrenal cortex (due to hyperplasia, adenoma, or carcinoma)." — Merck Manual Professional

Renin normally drives aldosterone, so aldosterone that stays high while renin is suppressed has escaped its control. The old cue for testing was hypertension plus low potassium. In 2025 the Endocrine Society dropped the selection:

"We suggest that all individuals with hypertension be screened for PA by measuring aldosterone and renin and determining the aldosterone to renin ratio, and that subsequent clinical care be guided by the results." — Adler et al., guideline

It is graded a weak suggestion on low-certainty evidence. The condition is not rare: when everyone was given a confirmatory suppression test regardless of their aldosterone and renin values, overt disease appeared in roughly one in nine people with stage 1 hypertension and more than one in five with resistant hypertension. It carries stroke and atrial fibrillation risk above that of ordinary hypertension, and the first-line drug, spironolactone, is cheap and widely available.

Against that, the test is barely used and the screening value is unproven. Among US veterans with apparently treatment-resistant hypertension, "4277 (1.6%) patients who were tested for primary aldosteronism were identified." (Cohen et al., Ann Intern Med). The ratio itself misses cases — "The aldosterone-renin ratio had poor sensitivity and negative predictive value for detecting biochemically overt primary aldosteronism" (Brown et al.) — and one blood draw is a noisy snapshot: "The mean intraindividual variability, expressed as coefficients of variation, was 31% for aldosterone and 45% for the aldosterone-to-renin ratio." (Yozamp et al., Hypertension). The threshold also depends on the instrument, since mass spectrometry gives lower aldosterone values than immunoassay.

Why it matters: a common cause of a very common disease, with a cheap test and a generic drug, where the first step of the chain is mostly not taken — and where today's randomised prompt moved the ordering without yet moving the diagnoses.

Worth knowing

Reported diagnostic performance piles up on round numbers. More than fifteen thousand reported discrimination values from two thousand articles in first-quartile journals in a single year: "We found a striking excess of results near perfect prediction and at multiples of five and ten", and "Around 1 in 40 AUC values were reported outside of their confidence intervals" (Gibson et al., medRxiv, CC BY-NC 4.0). The largest excess is at perfect prediction, with a compensating deficit just below it.

Moving a glaucoma classifier to another dataset costs the discrimination, and the operating point goes first. "Mean in-domain AUC was 0.913 and cross-source AUC was 0.702, a drop of 0.211", and "At thresholds set on the source validation data, specificity fell from 0.870 to 0.506 and sensitivity from 0.831 to 0.726." Resetting the threshold on a tenth of the target images traded specificity back for sensitivity and barely moved balanced accuracy; training on several sources did not help (Rahman et al., arXiv, CC BY 4.0). This connects with the recent finding that carrying a fetal-biometry model from a hospital cart to a handheld probe was degraded most by an unreported preprocessing choice.

Health systems and policy

Switzerland drops routine comparative efficacy trials for most biosimilars

"bei gut charakterisierten biologischen Wirkstoffen nicht mehr grundsätzlich erforderlich" (translated from German: "no longer generally required for well-characterised biological active substances") — Swissmedic

The revised guidance follows the European Medicines Agency's reflection paper, under which structural and functional comparability combined with pharmacokinetic data may suffice. No source quantifies what the change saves.

Philanthropy gets an earmarked channel for malaria

"a new financing mechanism designed to mobilize and deploy substantial additional restricted financial contributions" — Global Fund

No figure is attached. The context is a multi-billion-dollar shortfall and an incoming leadership facing choices about whether to stay focused on three diseases; this adds money restricted to one of them. At the fair pricing forum the same week, the access organisation argued that "The reliance on market dynamics and voluntary actions to address pricing issues needs to be changed." (MSF Access).

Where nobody verified, the declared numbers drifted

In three provinces of the Democratic Republic of Congo, performance-based payments rest on facility-reported activity, and verification was switched to a risk-based sample.

"In Kwilu, the gap between declared and validated figures was 19%. It reached 54% in Kasaï Central and 65% in Kasaï, where facilities that were not verified reported less carefully." — DHIS2 Community

Verification cost per quarter fell by about a quarter in the province with the smallest gap. The post is written by a firm involved in the work and names no outside evaluator.

Why it matters: if payment depends on self-reported figures, the design for checking them is part of the measurement — and on this account the unchecked facilities reported differently.

Mitochondrial replacement is being sold outside the indication it was licensed for

"as an all-purpose add-on, despite a lack of clear evidence" — STAT

In the United Kingdom the technique is restricted to people at high risk of passing on serious mitochondrial disease, with one licensed clinic. Commercial clinics elsewhere offer it as a fertility add-on; the safety argument in both settings turns on the same measurement, how much of the mother's mitochondrial DNA ends up in the child, and reported levels vary widely.

AI: using it well

Chemistry calculations kept out of the model. A research blog packages cheminformatics as agent skills with a stated division of labour: "the underlying language model handles workflow orchestration, database navigation and scientific reasoning, while deterministic chemistry tools execute molecular calculations", ending with the caveat that "computational designs are testable hypotheses, not finished drugs" (Google DeepMind). No benchmark, no paper, no synthesis.

Frontier models lose track of changing values as the document grows. On a new state-tracking benchmark, "accuracy fell sharply as inputs grew longer, dropping to 13% or lower on the longest general finite problems", while small recurrent and hybrid models trained directly on the task generalised to tens of thousands of assignments (Ai2). Asking a model to follow a patient's current medication list through a long record is this task.

Research taste, measured. Across more than ninety thousand generated proposals, agents reached "about 26% of the human level on citation matching and only 18% on idea matching" (IdeaTaste), and in blinded review experts flagged most generated proposals as such.

Repos and tools

A research prototype generates cryptographic proofs that a response came from a committed model while the weights stay secret, at around 110 tokens per second of prefill on one GPU for a 400-billion-parameter model, verified in seconds, at roughly seventy to ninety-five times the cost of plain serving and limited to greedy decoding and short contexts (Anthropic, with EPFL and MIT). A repository offers "The world's law in git: any provision, any country, any date, and the law that wrote each word." with no statement of coverage or correctness (lexifina/global-law). And NVIDIA's auto-ontology drafts an ontology from database metadata, then asks people to review and certify the definitions (repo) — enterprise databases, not biology.

Startups and deals

A mass spectrometry incumbent buys a separation technology and names blood screening as the goal. Waters acquired MOBILion Systems, whose high-resolution ion mobility separates molecules by shape before they reach the detector: the pitch is "expanding our menu into blood-based screening for early detection" (earnings call). Terms undisclosed, no performance data.

Time added to microscopes you already own. A seed round for a perfusion and imaging rig that keeps human tissue alive on standard inverted microscopes: "We started Vitroscope because living tissue cannot be reduced to a snapshot." (tech.eu). Separately, a single-dose dry powder inhaler "made predominantly from cardboard and is the size and shape of a credit card." raised money for manufacturing and a small trial (tech.eu).

The base rate. "A total of 66% of global funding was in AI-driven companies in October." (Crunchbase News)

Patents

Blood pressure predicted from a phone's own camera and flashlight, with no added sensor, where "the light module is a flashlight of the terminal device" (US 12,778,432). Bases and methylation recovered together by comparing the two strands of one DNA molecule, "without a need for external reference sequence alignment" (US 12,781,275). And vibrational imaging turned into a readout of what cells are doing, "based on a spectral shift of each of the at least one molecular probe caused by the biological activity" (US 12,782,273).

Other frontiers

A chip that untangles laser light. "Stanford engineers and colleagues designed a chip that can take a muddled mixture of light from multiple lasers and output clean beams of light." (Phys.org) The sorting happens in the chip's own architecture, demonstrated on two and then three lasers, with no real sample and no error rate reported.

Two markers on one vesicle, where neither alone separated anyone. Reading extracellular vesicles individually rather than in bulk: "Neither DPYS nor miR-1246 alone clearly distinguished the patient groups." (Phys.org) In cultured kidney cells the method saw a shift that bulk quantitative PCR did not.

A gripper on four cables, for a whole room. "Open source and air gappable" (Neufangled Robotics) — under $800, published CAD and boards, which changes the cost of collecting manipulation data outside a laboratory.

Big tech

Marvell agreed to buy Lumentum in "an all-stock acquisition of Lumentum initially valued at $115 billion", bringing silicon and photonic components for optical interconnects together, with completion pencilled in for 2028 (optics.org). A European fintech moved its default coding model to a self-hosted open-weights one, reporting that it "cost about a tenth of using OpenAI's Codex or Anthropic's Claude Code" without displacing them entirely (The Register).

Corners of the web

Respiratory therapists describe what decides whether someone can die at home on breathing support, and it is oxygen flow and road distance: "There is no way to deliver 100% O2 at home like that, but they wanted to die at home, with their dog." and "It is dependent on how far they live from the hospital, we've had some who wanted to do this but lived over an hour way and EMS would not transport." (r/respiratorytherapy)

People and good examples

Ten years of school-based HPV vaccination in South Africa, measured in girls living with HIV too

"Across all participants, infections with HPV types 16 and 18 fell by 83% between pre-vaccine and post-vaccine groups." — VaccinesWork

"The programme performed equally well among girls living with HIV. In this group, HPV 16/18 infections fell from 29% to 4%, representing an 82% reduction." — same

The comparison is between girls just too old to be eligible when the programme started and girls of the same age who were eligible, and the internal check is that other HPV types did not fall. The authors are describing their own study, and note that "it is still too early to measure the programme's success by looking at cancer rates alone."

Also this week, tributes to Robert Kyle, who read serum protein patterns at the Mayo Clinic and named both the small monoclonal spike in otherwise well people and the smouldering stage before disease: "These were not simply new terms; they created the framework through which we came to understand myeloma as a disease that develops over time." (OncoDaily)

Reads and ideas

Trieste kept the asylum's budget and its director. "The funds that had been spent running the sprawling asylum didn't disappear, as they did when mental hospitals were shuttered in the US." (MindSite News) An advocate of the model adds the part that does not travel: "The community system was built from scratch and was a result, not a starting point of the revolution." (Psychiatry at the Margins)

Scarcity as something taught. On Paul Farmer: "he rejected the socialization for scarcity, which is ordinarily built into public health training and work." The same tribute records the limit his students found, that his scope and scale "could not be replicated" (Think Global Health).

A disease told as a finished success, seen from the fraction it missed. A geneticist with cystic fibrosis that the modulator drugs cannot treat, on his own lipid design work: "Interestingly, the AI model hated this decision, but I ignored it, recognizing that because its training data had few direct comparisons that could isolate the effect of ester bonds, its predictions would be brittle" (Asimov Press).

Book of the day

Out of the Crisis — W. Edwards Deming (1982, renamed 1986). Concept: common causes and special causes

The distinction, stated later in a healthcare review: "improvement under common-cause variation requires action on the process, whereas special-cause variation merits an investigation to first find the cause." (Mohammed et al., BMJ Quality & Safety) The demonstration is a marble dropped through a funnel at a target: leaving the funnel alone does best, and compensating for the last miss does worse — "if anyone adjusts a stable process to try to compensate for a result that is undesirable, or a result that is extra good, the output that follows will be worse than if he had left the process alone" (course page).

Two cautions travel with it. The funnel result assumes a stable process, which an epidemic or a heatwave is not. And the same review warns that with very large samples the simple control chart gives limits so tight that nearly everything looks like a special cause, which can "potentially misguide the user into taking the wrong actions."

Why it matters: anyone building a system that watches many places at once has to say in advance what movement means leave it alone, and the chart that does that work stops working at the scale such a system operates on.